Literature DB >> 6330359

Synthesis, characterization, and properties of a group of platinum (IV) complexes.

R J Brandon, J C Dabrowiak.   

Abstract

The synthesis, characterization, and antitumor properties of a group of platinum (IV) complexes is presented. The compounds, formed by oxidation of cis-dichlorodiammineplatinum (II) (1) or its cis-dihydroxo analogue, were characterized by elemental analysis and infrared and 195Pt NMR spectroscopies. EPR studies of aqueous solutions containing the spin trap phenyl-tert-butylnitrone and various platinum(IV) complexes revealed that the compounds are incapable of producing radical species which may in turn cause DNA breakage. It appears that the antitumor activity of the compounds is either due to Pt(IV) binding via ligand displacement to important cellular components or through the ability of the compounds to undergo in vivo reduction to platinum (II) species, which in turn exert their cytotoxic effects in a manner analogous to 1. As a group, the platinum(IV) compounds were found to be significantly less active against L-1210 leukemia than the parent platinum(II) complex, 1.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6330359     DOI: 10.1021/jm00373a009

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Oxidative halogenation of cisplatin and carboplatin: synthesis, spectroscopy, and crystal and molecular structures of Pt(IV) prodrugs.

Authors:  Timothy C Johnstone; Sarah M Alexander; Justin J Wilson; Stephen J Lippard
Journal:  Dalton Trans       Date:  2015-01-07       Impact factor: 4.390

Review 2.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

3.  Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.

Authors:  Einav Ratzon; Yousef Najajreh; Rami Salem; Hazem Khamaisie; Martin Ruthardt; Jamal Mahajna
Journal:  BMC Cancer       Date:  2016-02-23       Impact factor: 4.430

4.  Oxidative Reactivity and Cytotoxic Properties of a Platinum(II) Complex Prepared by Outer-Sphere Amide Bond Coupling.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Polyhedron       Date:  2013-07-13       Impact factor: 3.052

5.  Synthesis and anticancer activity of two highly water-soluble and ionic Pt(iv) complexes as prodrugs for Pt(ii) anticancer drugs.

Authors:  Anli Gao; Yaxi Wu; Juan Yu; Hongyu Gong; Jing Jiang; Caihong Yang; Weiping Liu; Chen Qing
Journal:  RSC Med Chem       Date:  2022-03-18

Review 6.  Advances in platinum cancer chemotherapy. Advances in the design of cisplatin analogues.

Authors:  P C Hydes; M J Russell
Journal:  Cancer Metastasis Rev       Date:  1988-04       Impact factor: 9.264

7.  Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position.

Authors:  Dina Tolan; Valentina Gandin; Liam Morrison; Ahmed El-Nahas; Cristina Marzano; Diego Montagner; Andrea Erxleben
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

8.  In vitro evaluation of folic acid-conjugated redox-responsive mesoporous silica nanoparticles for the delivery of cisplatin.

Authors:  Merlis P Alvarez-Berríos; Juan L Vivero-Escoto
Journal:  Int J Nanomedicine       Date:  2016-11-23

9.  A novel class of bis- and tris-chelate diam(m)inebis(dicarboxylato)platinum(IV) complexes as potential anticancer prodrugs.

Authors:  Hristo P Varbanov; Simone Göschl; Petra Heffeter; Sarah Theiner; Alexander Roller; Frank Jensen; Michael A Jakupec; Walter Berger; Mathea Sophia Galanski; Bernhard K Keppler
Journal:  J Med Chem       Date:  2014-07-30       Impact factor: 7.446

10.  Click Pt(IV)-Carbohydrates Pro-Drugs for Treatment of Osteosarcoma.

Authors:  Eoin Moynihan; Giada Bassi; Andrea Ruffini; Silvia Panseri; Monica Montesi; Trinidad Velasco-Torrijos; Diego Montagner
Journal:  Front Chem       Date:  2021-12-07       Impact factor: 5.221

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.